Price$3.09-0.09 (-2.83%)
01:30 PM08:00 PM
News · 26 weeks65-33%
2026-04-192026-10-11
Mix2490d
- Insider8(33%)
- SEC Filings6(25%)
- Other5(21%)
- Market3(13%)
- Earnings2(8%)
Latest news
25 items- NEWSLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Ardelyx, Inc. Lawsuit - ARDXNEW YORK CITY, NY / ACCESS Newswire / October 16, 2026 / Levi & Korsinsky, LLP notifies investors in Ardelyx, Inc. (NASDAQ:ARDX) that Eric Foster, the Company's Chief Commercial Officer, is named as an individual defendant in a securities class action brought on behalf of shareholders who purchased securities between January 13, 2025 and August 6, 2026. Find out if you could qualify to recover your per-share losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.ARDX closed at $4.87 on August 6, 2026 and fell to $4.00 the following session, a one-day decline of $0.87 per share, or approximately 18%. The lead plaintiff deadline is November 16, 2026.Eric
- PRArdelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-CWALTHAM, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced results from a real-world analysis being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting showing that gastrointestinal-related healthcare resource utilization (GI-HCRU) dropped significantly after adults with irritable bowel syndrome with constipation (IBS-C) started IBSRELA® (tenapanor). Ardelyx will also present data on how IBS-C symptom burden affects quality of life, along with the design and
- NEWSLevi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 16, 2026 - ARDXNEW YORK CITY, NY / ACCESS Newswire / October 9, 2026 / Levi & Korsinsky, LLP notifies investors in Ardelyx, Inc. (NASDAQ:ARDX) that a class action has been filed on behalf of shareholders who purchased securities between January 13, 2025 and August 6, 2026. Find out if you may be eligible to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.ARDX shares fell approximately 18%, a decline of $0.87 per share, after the Company's August 6, 2026 announcement reducing full-year 2026 IBSRELA revenue guidance and withdrawing its long-term XPHOZAH revenue guidance. The window to apply for lead plaintiff closes on November 16, 2026.The Named Individ
- PRArdelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced three abstracts will be presented at the American Society of Nephrology (ASN) Kidney Week 2026, taking place October 21–25, 2026 in Denver, Colorado. The poster presentations will highlight new research pertaining to the hyperphosphatemia treatment landscape, including real-world evidence evaluating the effectiveness of tenapanor with different phosphate binders, patient perspectives on the challenges of managing hyperphosphatemia, and a
- NEWSARDX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Ardelyx, Inc. Securities Lawsuit - Contact Levi & KorsinskyNEW YORK CITY, NY / ACCESS Newswire / October 2, 2026 / Levi & Korsinsky, LLP notifies institutional investors in Ardelyx, Inc. (NASDAQ:ARDX), including pension funds, asset managers, and other fiduciaries, that a securities class action has been filed on behalf of shareholders who purchased ARDX securities between January 13, 2025 and August 6, 2026. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.ARDX closed at $4.87 per share on August 6, 2026 and fell to $4.00 per share the following session, a one-day decline of $0.87 per share, or approximately 18%. The window to apply for lead plaintiff appointme
- PRArdelyx Earns Multiple Honors at the 2026 PM360 Trailblazer AwardsWALTHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that it received multiple honors at the 2026 PM360 Trailblazer Awards, recognizing the company, its leadership, and the work of teams across the organization. Ardelyx received the following awards: Life Sciences Manufacturer CEO of the Year: Mike RaabPodcast Initiative Gold Winner: Gut Matters: Discoveries and InnovationsMarketing Team of the Year Silver Winner: IBSRELA Marketing Team "We are honored to receive this recognition from P
- PRArdelyx to Participate in Upcoming Investor ConferencesWALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (NASDAQ:ARDX), ("Ardelyx" or the "Company") a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following investor conferences: Citi's 2026 Biopharma Back to School ConferenceLocation: New York, NYInvestor Meetings: Wednesday, September 9 2026 Cantor Global Healthcare ConferenceLocation: New York, NYFireside Chat: Thursday, September 10 at 11:30 AM ETInvestor Meetings: Thursday, September 10 Morgan Stanley 24th Annual Global Healthcare ConferenceLocation: New York, NYFireside
- INSIDERChief Financial Officer Hohenleitner Susan sold $6,009 worth of shares (1,558 units at $3.86), decreasing direct ownership by 0.68% to 227,520 units (SEC Form 4) to cover withholding tax4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDEROfficer Reilly Joseph James sold $15,358 worth of shares (3,982 units at $3.86), decreasing direct ownership by 3% to 145,854 units (SEC Form 4) (for tax liability)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDEROfficer Bishop John E sold $76,174 worth of shares (19,750 units at $3.86), decreasing direct ownership by 6% to 317,095 units (SEC Form 4) to cover taxes4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Human Resources Officer Brady James Parker sold $58,378 worth of shares (15,136 units at $3.86), decreasing direct ownership by 6% to 245,930 units (SEC Form 4) (tax withholding)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Commercial Officer Foster Eric Duane sold $33,023 worth of shares (8,562 units at $3.86), decreasing direct ownership by 2% to 409,410 units (SEC Form 4) to cover withholding tax4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Business Officer Kelliher Mike sold $29,922 worth of shares (7,758 units at $3.86), decreasing direct ownership by 2% to 349,660 units (SEC Form 4) (tax liability)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Patient Officer Williams Laura A sold $41,419 worth of shares (10,739 units at $3.86), decreasing direct ownership by 3% to 367,456 units (SEC Form 4) (tax liability)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERPresident & CEO Raab Michael sold $225,914 worth of shares (58,574 units at $3.86), decreasing direct ownership by 3% to 1,619,792 units (SEC Form 4) (withholding obligation)4 - ARDELYX, INC. (0001437402) (Issuer)
- SECSEC Form 144 filed by Ardelyx Inc.144 - ARDELYX, INC. (0001437402) (Subject)
- SECSEC Form 144 filed by Ardelyx Inc.144 - ARDELYX, INC. (0001437402) (Subject)
- SECSEC Form 8-K filed by Ardelyx Inc.8-K - ARDELYX, INC. (0001437402) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ardelyx Inc.SCHEDULE 13G/A - ARDELYX, INC. (0001437402) (Subject)
- SECSEC Form S-8 filed by Ardelyx Inc.S-8 - ARDELYX, INC. (0001437402) (Filer)
- SECSEC Form 10-Q filed by Ardelyx Inc.10-Q - ARDELYX, INC. (0001437402) (Filer)
- SECArdelyx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ARDELYX, INC. (0001437402) (Filer)
- PRArdelyx Reports Second Quarter 2026 Financial Results and Provides Business UpdateQ2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue growth of 27% year-over-year to $31.9 million Strong financial position with $281.8 million in cash, cash equivalents and investments as of June 30, 2026 Revising FY 2026 and long-term guidance Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (NASDAQ:ARDX), ("Ardelyx" or the "Company") a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs,
- PRArdelyx to Report Second Quarter 2026 Financial Results on August 6, 2026WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX) ("Ardelyx" or the "Company"), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Thursday, August 6, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the second quarter of 2026. Webcast InformationA live webcast of the conference call and accompanying slides will be available in the "Events and Presentations" section under "News and Events" within the Investors section of the Compan
- INSIDERPresident & CEO Raab Michael exercised 20,834 shares at a strike of $0.99 and sold $210,923 worth of shares (41,668 units at $5.06) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,678,366 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
ARDX FAQ
7 questionsWhat does Ardelyx Inc. do?
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of...Where does ARDX stock trade?
Ardelyx Inc. (ARDX) is listed on NASDAQ.What sector and industry is ARDX in?
Ardelyx Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ardelyx Inc. go public?
Ardelyx Inc. (ARDX) completed its IPO in 2014.What are analysts saying about ARDX?
Ardelyx Inc. has had 8 recent analyst actions on file. The most recent action was from Ladenburg Thalmann: Buy with a $1600.00 price target on 2026-06-16. Recent price targets range from $550.00 to $1600.00.What companies are similar to ARDX?
Notable peers in the same industry include KDNY (Chinook Therapeutics Inc.), AKBA (Akebia Therapeutics Inc.), ZSAN (Zosano Pharma Corporation). Compare ARDX side-by-side with any of them on Quantisnow.How can I track ARDX on Quantisnow?
Quantisnow aggregates Ardelyx Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARDX to receive live email and push alerts on every new disclosure.